- William Blair is keeping expectations low for Pharmacyclics' (PCYC +1.4%) ibrutinib, saying only that the investigational BTK inhibitor "could become the largest product in hematology oncology history."
- Cited in the report: The agent's potential in "almost all B-cell malignancies," its "best combined efficacy and safety profile," its first to market status, its potential to expand into more indications and move to frontline and maintenance settings from the relapsed/refractory setting, and a lack of competition.
- PCYC initiated at Buy.
- Price target is $143, representing a 20% upside from Monday's close.
William Blair has high hopes for Pharmacyclics' ibrutinib
From other sites
at CNBC.com (Jan 13, 2015)
at CNBC.com (Dec 5, 2014)
at CNBC.com (Sep 17, 2014)
at CNBC.com (Jul 29, 2014)
at CNBC.com (Jul 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs